Showing 5 posts of 5 posts found.

Boehringer assures future growth following sales drop

April 23, 2015
Sales and Marketing Boehringer, COPD, Glyxambi, Striverdi Respimat, empagliflozin, empagliflozin/linagliptin, financials, full year, jardiance, nintedanib, ofev, olodaterol, results

Boehringer says it is positioned for future growth in the wake of filing a decline in profit for 2014 and …

Strivrerdi image

Boehringer complaint ruled out by PMCPA

January 15, 2015
Medical Communications, Sales and Marketing ABPI, Boehringer, COPD, PMCPA, Striverdi, olodaterol

A complaint made by a pharmacist stating that the artwork image for Boehringer Ingelheim’s COPD drug Striverdi is misleading has …

Boehringer spends €100 million on inhaler

September 30, 2014
Manufacturing and Production, Sales and Marketing Boehringer, Germany, Spiriva, Striverdi, inhaler, olodaterol, respimat

Boehringer Ingelheim is to spend more than €100 million at its Dortmund site in Germany in order to expand the …


Boehringer’s Striverdi gains FDA approval

August 1, 2014
Sales and Marketing Advair, COPD, Pfizer, Spiriva, asthma, olodaterol

Boehringer Ingelheim’s new lung drug Striverdi has gained US approval for patients with chronic obstructive pulmonary disorder. Striverdi Respimat (olodaterol), …

Boehringer’s COPD drug passes hurdle

May 23, 2012
Research and Development, Sales and Marketing Boehringer, COPD, Daxas, Relovair, Spiriva, olodaterol

Boehringer Ingelheim’s once-daily bronchodilator olodaterol has improved lung function versus placebo in a Phase II trial.  The manufacturer wants the …

Latest content